Kreitman, Robert J.
Dearden, Claire
Zinzani, Pier Luigi
Delgado, Julio
Karlin, Lionel
Robak, Tadeusz
Gladstone, Douglas E. http://orcid.org/0000-0001-8484-2990
le Coutre, Philipp
Dietrich, Sascha
Gotic, Mirjana http://orcid.org/0000-0002-8590-0328
Larratt, Loree
Offner, Fritz
Schiller, Gary
Swords, Ronan
Bacon, Larry
Bocchia, Monica
Bouabdallah, Krimo
Breems, Dimitri A.
Cortelezzi, Agostino
Dinner, Shira
Doubek, Michael
Gjertsen, Bjorn Tore http://orcid.org/0000-0001-9358-9704
Gobbi, Marco
Hellmann, Andrzej
Lepretre, Stephane
Maloisel, Frederic
Ravandi, Farhad
Rousselot, Philippe
Rummel, Mathias
Siddiqi, Tanya
Tadmor, Tamar
Troussard, Xavier
Yi, Cecilia Arana
Saglio, Giuseppe
Roboz, Gail J.
Balic, Kemal
Standifer, Nathan
He, Peng
Marshall, Shannon
Wilson, Wyndham
Pastan, Ira
Yao, Nai-Shun
Giles, Francis
Article History
Received: 6 June 2018
Accepted: 8 June 2018
First Online: 20 July 2018
Compliance with ethical standards
:
: This study was sponsored by MedImmune. RJK received a research grant from MedImmune and is co-inventor of moxetumomab pasudotox, with the NIH holding the patent. CD has received personal fees from Gilead, Infinity, Janssen/Pharacyclics, MedImmune, Roche, and Sanofi Aventis, and has received clinical trial support from MedImmune. PLZ has served as an advisor for Bristol-Myers Squibb, Celgene, Gilead, Janssen, Merck, Roche, Servier, and Takeda. JD served on a data monitoring board for MedImmune, has received research grants from Janssen and Roche, and has received personal fees from Abbvie, Gilead, Janssen, and Roche. LK, DEG, M Gotic, LL, FO, RS, GS, SD, LB, CAY, AH, KB, MB, MG, AC, MD, SD, SL, MR, PR, TT, GS, GJR, XT, and WW have no conflicts to report. TR has received research grants from AstraZeneca. PLC has served as a speaker for Bristol-Myers Squibb, Incyte, Novartis, and Pfizer. DAB has received personal fees from Amgen, Novartis, and Teva, and his institution has received reimbursement for clinical trials from Ablynx, Amgen, Astellas, Astex, Cyclacel, Genzyme, Janssen, MedImmune, Merus, Menarini, Novella Clinical, Pfizer, and Seattle Genetics. BTG has received personal fees from BerGenBio AS, Novartis AS, Pfizer, and Seattle Genetics, received non-financial support from Merck Sharpe & Dohme and Roche, and owns shares in Alden Cancer Therapeutics 2 AS and Kinn Therapeutics AS. FM has received research grants from Amgen and Sandoz, received travel accommodations from Octapharma and Roche, and served on advisory boards for Pfizer, Roche, and Sandoz. FR has received research grants from MedImmune. TS has served on speakers’ bureaus for Pharmacyclics and Seattle Genetics, and on a steering committee for Juno. KB, NS, PH, SM, and NSY are employees of MedImmune and may own stock/options in AstraZeneca. IP is co-inventor of moxetumomab pasudotox, with the NIH holding the patent. FG has received a research grant from MedImmune.